Podcast appearances and mentions of John C Byrd

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Guest: John C. Byrd, MD For patients with chronic lymphocytic leukemia, molecular analysis can provide critical information. Dr. John C. Byrd discusses the importance of IGHV and TP53 sequencing and the clinical value they provide.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

Two doctors with very different journeys were honored by CURE for their efforts to improve the quality of life for those affected by chronic lymphocytic leukemia (CLL). At the 2018 CLL Heroes Award ceremony, John C. Byrd, M.D., a researcher and clinical specialist at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital, and Brian Koffman, M.D.C.M., a family doctor who has been diagnosed with CLL and co-founded the CLL Society, were both honored at the event. This week, both winners tell us more about what they have accomplished in this space, and why being a CLL Hero is important to them. For more information, visit: [curetoday.com](https://www.curetoday.com/articles/cll-heroes-honored-by-cure).